448 related articles for article (PubMed ID: 8640670)
1. Endometrial carcinoma associated with breast carcinoma: low incidence with tamoxifen use.
Cuenca RE; Giachino J; Arredondo MA; Hempling R; Edge SB
Cancer; 1996 May; 77(10):2058-63. PubMed ID: 8640670
[TBL] [Abstract][Full Text] [Related]
2. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
3. The incidence of subsequent endometrial carcinoma with tamoxifen use in patients with primary breast carcinoma.
Katase K; Sugiyama Y; Hasumi K; Yoshimoto M; Kasumi F
Cancer; 1998 May; 82(9):1698-703. PubMed ID: 9576291
[TBL] [Abstract][Full Text] [Related]
4. Indication of hysteroscopy in tamoxifen treated breast cancer patients.
Taponeco F; Curcio C; Fasciani A; Giuntini A; Artini PG; Fornaciari G; Petraglia F; Genazzani AR
J Exp Clin Cancer Res; 2002 Mar; 21(1):37-43. PubMed ID: 12071527
[TBL] [Abstract][Full Text] [Related]
5. Relationship between tamoxifen use and high risk endometrial cancer histologic types.
Bland AE; Calingaert B; Secord AA; Lee PS; Valea FA; Berchuck A; Soper JT; Havrilesky L
Gynecol Oncol; 2009 Jan; 112(1):150-4. PubMed ID: 18937966
[TBL] [Abstract][Full Text] [Related]
6. Outcomes in patients with primary breast cancer and a subsequent diagnosis of endometrial cancer : comparison of cohorts treated with and without tamoxifen.
Saadat M; Truong PT; Kader HA; Speers CH; Berthelet E; McMurtrie E; Olivotto IA
Cancer; 2007 Jul; 110(1):31-7. PubMed ID: 17510927
[TBL] [Abstract][Full Text] [Related]
7. Comparison of endometrial changes among symptomatic tamoxifen-treated and nontreated premenopausal and postmenopausal breast cancer patients.
Cheng WF; Lin HH; Torng PL; Huang SC
Gynecol Oncol; 1997 Aug; 66(2):233-7. PubMed ID: 9264568
[TBL] [Abstract][Full Text] [Related]
8. Is tamoxifen associated with high-risk endometrial carcinomas? A retrospective case series of 196 women with endometrial cancer.
Rieck GC; Freites ON; Williams S
J Obstet Gynaecol; 2005 Jan; 25(1):39-41. PubMed ID: 16147692
[TBL] [Abstract][Full Text] [Related]
9. [Risk of endometrial hyperplasia and carcinoma in breast cancer patients receiving adjuvant tamoxifen].
Semiglazov VF; Maksimov SIa; Bulgatova EA; Meshkova IE; Chepik OF; Berstein LM
Vopr Onkol; 2003; 49(2):198-204. PubMed ID: 12785205
[TBL] [Abstract][Full Text] [Related]
10. Endometrial cancer in patients with breast carcinoma treated with tamoxifen: report of two cases and the literature overview.
Sliwińska M; Wojtacki J; Sliwiński W
Med Sci Monit; 2000; 6(2):399-406. PubMed ID: 11208346
[TBL] [Abstract][Full Text] [Related]
11. Endometrial cancer after tamoxifen treatment: a descriptive study of 25 breast cancer patients who subsequently developed endometrial cancer.
Peters-Engl C; Medl M; Danmayr E; Mirau M; Alth G; Leodolter S
Anticancer Res; 1996; 16(5B):3241-6. PubMed ID: 8920798
[TBL] [Abstract][Full Text] [Related]
12. A retrospective study of tamoxifen and endometrial cancer in breast cancer patients.
Robinson DC; Bloss JD; Schiano MA
Gynecol Oncol; 1995 Nov; 59(2):186-90. PubMed ID: 7590470
[TBL] [Abstract][Full Text] [Related]
13. [Adjuvant therapy of breast cancer with tamoxifen and endometrial carcinoma].
Mignotte H; Sasco AJ; Lasset C; Saez S; Rivoire M; Bobin JY
Bull Cancer; 1992; 79(10):969-77. PubMed ID: 1292764
[TBL] [Abstract][Full Text] [Related]
14. Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study.
Swerdlow AJ; Jones ME;
J Natl Cancer Inst; 2005 Mar; 97(5):375-84. PubMed ID: 15741574
[TBL] [Abstract][Full Text] [Related]
15. The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study.
Beiner ME; Finch A; Rosen B; Lubinski J; Moller P; Ghadirian P; Lynch HT; Friedman E; Sun P; Narod SA;
Gynecol Oncol; 2007 Jan; 104(1):7-10. PubMed ID: 16962648
[TBL] [Abstract][Full Text] [Related]
16. Does tamoxifen use affect prognosis in breast cancer patients who develop endometrial cancer?
Slomovitz BM; Sun CC; Ramirez PT; Bodurka DC; Diaz P; Lu KH
Obstet Gynecol; 2004 Aug; 104(2):255-60. PubMed ID: 15291996
[TBL] [Abstract][Full Text] [Related]
17. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.
Mariotto AB; Feuer EJ; Harlan LC; Abrams J
J Natl Cancer Inst Monogr; 2006; (36):7-15. PubMed ID: 17032888
[TBL] [Abstract][Full Text] [Related]
18. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.
Fisher B; Costantino JP; Wickerham DL; Cecchini RS; Cronin WM; Robidoux A; Bevers TB; Kavanah MT; Atkins JN; Margolese RG; Runowicz CD; James JM; Ford LG; Wolmark N
J Natl Cancer Inst; 2005 Nov; 97(22):1652-62. PubMed ID: 16288118
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathologic study of 56 patients with endometrial cancer during or after adjuvant tamoxifen use for their breast cancers.
Hachisuga T; Saito T; Kigawa J; Ohwada M; Yamazawa K; Yasue A; Iwasaka T; Sugiyama T; Kita T; Nagai N
Gynecol Oncol; 2004 Oct; 95(1):139-44. PubMed ID: 15385123
[TBL] [Abstract][Full Text] [Related]
20. The nature of tamoxifen action in the control of female breast cancer.
Kodama M; Kodama T
In Vivo; 2001; 15(4):319-25. PubMed ID: 11695224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
